SCHEMBL14320698

SCHEMBL14320698

CS(=O)(=O)c1cccc(Nc2nc(-c3cccc(S(C)(=O)=O)c3)nc3cn[nH]c23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.49
CYP1A2 P05177 4/20 0.45
CYP3A4 P08684 4/20 0.45
LMNA P02545 3/20 0.45
CYP2D6 P10635 3/20 0.45
MAPK1 P28482 3/20 0.45
CYP2C19 P33261 3/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM1A O60341 2/20 0.45
ABCG2 Q9UNQ0 2/20 0.45
ABCB1 P08183 1/20 0.45
EPHB4 P54760 2/20 0.43
USP2 O75604 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320275 0.89 ABCG2 (0.51) PIK3CAKDM1AABCG2ABCB1
SCHEMBL15650923 0.88 CYP1A2 (0.45) PIK3CACYP1A2CYP3A4LMNACYP2D6
SCHEMBL14320467 0.87 PIK3CA (0.41) PIK3CACYP1A2CYP3A4LMNACYP2D6
SCHEMBL14320503 0.85 ABCG2 (0.46) LMNAMAPK1KDM4EMAPTHPGD
SCHEMBL15651698 0.85 PDE5A (0.44) PIK3CAKDM1AABCG2ABCB1EPHB4
SCHEMBL14321128 0.85 MEN1 (0.47) PIK3CALMNAKDM4ETP53MAPT
SCHEMBL14320604 0.84 ULK1 (0.44) PIK3CACYP1A2CYP3A4LMNACYP2D6
SCHEMBL14320551 0.83 JAK2 (0.58) PIK3CALMNAMAPK1MAPTMEN1
SCHEMBL15651113 0.83 EPHB4 (0.42) PIK3CACYP1A2CYP3A4LMNACYP2D6
SCHEMBL14320900 0.81 SYK (0.50) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK PIK3CA 1016/4885CYP1A2 3832/4885CYP3A4 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.